Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 11, 2013 - Issue 3
Submit an article Journal homepage
119
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Benefits of delapril in hypertensive patients along the cardiovascular continuum

José Ramón González-Juanatey Cardiology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. [email protected]; Cardiology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, A Coruña, Spain. [email protected]
&
Alberto Cordero Cardiology Department, Hospital Universitario de San Juan, Sant Joan d`Alacant, Alicante, Spain; Cardiology Department, Hospital Universitario de San Juan, Sant Joan d`Alacant, Alicante, Spain
Pages 271-281 | Published online: 10 Jan 2014

References

  • Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 303(18), 1841–1847 (2010).
  • Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J. Hypertens. 27(5), 963–975 (2009).
  • Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369(9568), 1208–1219 (2007).
  • Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547–1559 (2008).
  • van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158,998 patients. Eur. Heart J. 33(16), 2088–2097 (2012).
  • Mancia G, De Backer G, Dominiczak A et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105–1187 (2007).
  • Mancia G, Laurent S, Agabiti-Rosei E et al.; European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 27(11), 2121–2158 (2009).
  • Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417–2428 (2008).
  • Weber MA, Bakris GL, Jamerson K et al.; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J. Am. Coll. Cardiol. 56(1), 77–85 (2010).
  • Bakris GL, Sarafidis PA, Weir MR et al.; ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375(9721), 1173–1181 (2010).
  • Saruta T, Nishikawa K. Characteristics of a new angiotensin converting enzyme inhibitor: delapril. Am. J. Hypertens. 4(1 Pt 2), 23S–28S (1991).
  • Ogihara T, Kaneko Y, Ikeda M et al. Clinical evaluation of delapril in Japan. Report from the Japan Study Group on Delapril. Am. J. Hypertens. 4(1 Pt 2), 42S–45S (1991).
  • Otero ML. Manidipine-delapril combination in the management of hypertension. Vasc. Health Risk Manag. 3(3), 255–263 (2007).
  • Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensin-converting enzyme inhibitor. Am. J. Cardiol. 75(18), 7F–12F (1995).
  • Bevilacqua M, Vago T, Rogolino A, Conci F, Santoli E, Norbiato G. Affinity of angiotensin I-converting enzyme (ACE) inhibitors for N- and C-binding sites of human ACE is different in heart, lung, arteries, and veins. J. Cardiovasc. Pharmacol. 28(4), 494–499 (1996).
  • Vago T, Bevilacqua M, Conci F, Rogolino A, Norbiato G. Pharmacologic data reveal the heterogeneity of angiotensin-converting enzyme according to its source (lung versus heart). Am. J. Cardiol. 75(18), 13F–17F (1995).
  • Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J. Cardiovasc. Pharmacol. 13(Suppl. 3), S59–S62 (1989).
  • Oka Y, Nishikawa K, Kito G et al. Delapril. Cardiovasc. Drug. Rev. 6(3), 192–205 (1988).
  • McCormack PL, Keating GM. Delapril/manidipine. Drugs 66(7), 961–969 (2006).
  • Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Rev. Cardiovasc. Ther. 5(2), 147–159 (2007).
  • Onoyama K, Nanishi F, Okuda S et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin. Pharmacol. Ther. 43(3), 242–249 (1988).
  • Duchin KL, McKinstry DN, Cohen AI, Migdalof BH. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin. Pharmacokinet. 14(4), 241–259 (1988).
  • Gomez HJ, Cirillo VJ, Irvin JD. Enalapril: a review of human pharmacology. Drugs 30(Suppl. 1), 13–24 (1985).
  • Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 53(3), 480–486 (2009).
  • Cordero A, Bertomeu-Martínez V, Mazón P et al. Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease. Rev. Esp. Cardiol. 64(7), 587–593 (2011).
  • Fletcher RD, Amdur RL, Kolodner R et al. Blood pressure control among US veterans: a large multiyear analysis of blood pressure data from the Veterans Administration health data repository. Circulation 125(20), 2462–2468 (2012).
  • Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373(9667), 929–940 (2009).
  • Omboni S, Fogari R, Mancia G. A smooth blood pressure control is obtained over 24 h by delapril in mild-to-moderate essential hypertensives. Blood Press. 10(3), 170–175 (2001).
  • Verdecchia P, Angeli F. Does brachial pulse pressure predict coronary events? Adv. Cardiol. 44, 150–159 (2007).
  • Dolan E, Stanton A, Thijs L et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46(1), 156–161 (2005).
  • Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N. Engl. J. Med. 354(22), 2368–2374 (2006).
  • Borghi C, Costa FV, Veronesi E, Cosentino E, Ambrosioni E. The role of ACE-inhibition in clinical practice: focus on delapril. High Blood Press. 9, 90–105 (2000).
  • Zannad F, Matzinger A, Larché J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am. J. Hypertens. 9(7), 633–643 (1996).
  • Fogari R, Zoppi A, Mugellini A, Vanasia A, Poletti L, Corradi L. Efficacy of delapril in the treatment of mild-to-moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Adv. Ther. 14(5), 254–261 (1997).
  • Mugellini A, Vaccarella A, Celentano A, Scanferla F, Zoppi A, Fogari R. Fixed combination of manidipine and delapril in the treatment of mild-to-moderate essential hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. Blood Press. Suppl. 1, 6–13 (2005).
  • Parati G, Omboni S, Rizzoni D, Agabiti-Rosei E, Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J. Hypertens. 16(11), 1685–1691 (1998).
  • Mizuno K, Niimura S, Fukuchi S. Delapril in the treatment of essential hypertension. An equipotent antihypertensive effect in elderly hypertensives and younger patients. Curr. Ther. Res. 50(3), 363–368 (1991).
  • Ogihara T, Ishikawa H, Mikami H et al. Effects of long-term treatment with delapril on quality of life in hypertensive patients. Curr. Ther. Res. 51(2), 254–260 (1992).
  • Ogihara T. Practitioner’s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am. J. Hypertens. 13(5 Pt 1), 461–467 (2000).
  • Martínez Martín FJ. Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. Expert Rev. Cardiovasc. Ther. 7(7), 863–869 (2009).
  • Martinez-Martin FJ, Saiz-Satjes M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. Expert Rev. Cardiovasc. Ther. 6(10), 1347–1355 (2008).
  • Zoppi A, Mugellini A, Preti P et al. Effects of the fixed combination of manidipine plus delapril in the treatment of hypertension inadequately controlled by monotherapy with either component: a Phase III, multicenter, open-label, clinical trial. Curr. Ther. Res. Clin. Exp. 64(7), 422–433 (2003).
  • Fogari R, Malamani G, Zoppi A et al. Effect on the development of ankle edema of adding delapril to manidipine in patients with mild-to-moderate essential hypertension: a three-way crossover study. Clin. Ther. 29(3), 413–418 (2007).
  • Mugellini A, Dobovisek J, Planinc D, Cremonesi G, Fogari R. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild-to-moderate essential hypertension: results of a randomized trial. Clin. Ther. 26(9), 1419–1426 (2004).
  • Karpati P, Alberici M, Tocci G, Musumeci MB, Cosentino F, Volpe M. Long-term tolerability and efficacy of the fixed combination of manidipine and delapril in patients with essential hypertension. High Blood Press. Cardiovasc. Prev. 10(2), 81–86 (2003).
  • Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with Type II diabetes mellitus. J. Hum. Hypertens. 18(10), 687–691 (2004).
  • Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with Type 2 diabetes mellitus. Hypertens. Res. 31(1), 43–50 (2008).
  • Roca-Cusachs A, Schmieder RE, Triposkiadis F et al.; MORE Study Group. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J. Hypertens. 26(4), 813–818 (2008).
  • Kohlmann O Jr, Roca-Cusachs A, Laurent S, Schmieder RE, Wenzel RR, Fogari R. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with Type 2 diabetes and microalbuminuria. Adv. Ther. 26(3), 313–324 (2009).
  • Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern. Med. 47(5), 361–366 (2008).
  • Cavalieri L, Cremonesi G. Delapril plus indapamide: a review of the combination in the treatment of hypertension. Clin. Drug Investig. 27(6), 367–380 (2007).
  • Rosei EA, Rizzoni D; DIMS II (Delapril-Indapamide Multicenter Study II). Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild-to-moderate essential hypertension: a randomised, multicentre, controlled study. J. Hum. Hypertens. 17(2), 139–146 (2003).
  • Cremonesi G, Cavalieri L, Cikes I et al. Fixed combinations of delapril plus indapamide vs fosinopril plus hydrochlorothiazide in mild-to-moderate essential hypertension. Adv. Ther. 19(3), 129–137 (2002).
  • Acanfora D, Lowenthal DT, Furgi G et al. The effects of delapril in combination with indapamide on glomerular filtration rate in elderly hypertensive patients. Am. J. Ther. 4(11-12), 405–408 (1997).
  • Acanfora D, Lowenthal DT, Furgi G et al. Effects of delapril in combination with indapamide on blood pressure and left ventricular mass in elderly hypertensive patients. Am. J. Ther. 5(1), 17–23 (1998).
  • Circelli M, Nicolini G, Egan CG, Cremonesi G. Efficacy and safety of delapril/indapamide compared to different ACE-inhibitor/hydrochlorothiazide combinations: a meta-analysis. Int. J. Gen. Med. 5, 725–734 (2012).
  • Friedman O, McAlister FA, Yun L, Campbell NR, Tu K; Canadian Hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am. J. Med. 123(2), 173–181 (2010).
  • Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. 117(3), 234–242 (1992).
  • Overlack A. ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management. Drug Saf. 15(1), 72–78 (1996).
  • Ogihara T, Mikami H, Katahira K, Otsuka A. Comparative study of the effects of three angiotensin converting enzyme inhibitors on the cough reflex. Am. J. Hypertens. 4(1 Pt 2), 46S–51S (1991).
  • Mahfoud F, Ukena C, Pöss J et al. Microalbuminuria independently correlates to cardiovascular comorbidity burden in patients with hypertension. Clin. Res. Cardiol. 101(9), 761–766 (2012).
  • Kaizu K, Feng Sun X, Uriu K et al. Comparison of the renal effects of different angiotensin-converting enzyme inhibitors in patients with chronic renal disease. Clin. Exp. Nephrol. 6, 30–37 (2002).
  • Deerochanawong C, Kornthong P, Phongwiratchai S, Serirat S. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive Type 2 diabetic patients with microalbuminuria. J. Med. Assoc. Thai. 84(2), 234–241 (2001).
  • Shiba T, Inoue M, Tada H et al. Delapril versus manidipine in hypertensive therapy to halt the Type-2-diabetes-mellitus-associated nephropathy. Diabetes Res. Clin. Pract. 47(2), 97–104 (2000).
  • Barrios V, Escobar C, Calderón A, Echarri R, González-Pedel V, Ruilope LM; CONTROLRISK Investigators. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J. Hum. Hypertens. 21(6), 479–485 (2007).
  • Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322(22), 1561–1566 (1990).
  • Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am. J. Hypertens. 16(11 Pt 1), 895–899 (2003).
  • Cerciello A, Galzerano D, Muto C, Nappi F, Giasi A, Giasi M. Efficacy and tolerance of delapril, a new ACE-inhibitors in essential hypertension (Abstract). J. Hypertens. 12(Suppl. 3), S141 (1994).
  • Tomiyama H, Kimura Y, Sakuma Y et al. Effects of an ACE inhibitor and a calcium channel blocker on cardiovascular autonomic nervous system and carotid distensibility in patients with mild-to-moderate hypertension. Am. J. Hypertens. 11(6 Pt 1), 682–689 (1998).
  • Yang EY, Chambless L, Sharrett AR et al. Carotid arterial wall characteristics are associated with incident ischemic stroke but not coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) study. Stroke. 43(1), 103–108 (2012).
  • Rodríguez-Mañero M, Cordero A, Bertomeu-González V et al. Impact of new criteria for anticoagulant treatment in atrial fibrillation. Rev. Esp. Cardiol. 64(8), 649–653 (2011).
  • Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J. Am. Coll. Cardiol. 55(21), 2299–2307 (2010).
  • Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 32(6), 965–971 (1998).
  • Folsom AR, Rosamond WD, Shahar E et al. Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100(7), 736–742 (1999).
  • Held C, Hjemdahl P, Håkan Wallén N et al. Inflammatory and hemostatic markers in relation to cardiovascular prognosis in patients with stable angina pectoris. Results from the APSIS study. The Angina Prognosis Study in Stockholm. Atherosclerosis 148(1), 179–188 (2000).
  • Atarashi K, Takagi M, Minami M, Kimura Y, Matsuoka H, Sugimoto T. Effects of manidipine and delapril on glucose and lipid metabolism in hypertensive patients with non-insulin-dependent diabetes mellitus. Blood Press. Suppl. 3, 130–134 (1992).
  • Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab. Res. Rev. 28(Suppl. 1), 8–14 (2012).
  • Malik RA, Williamson S, Abbott C et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 352(9145), 1978–1981 (1998).
  • Ruggenenti P, Lauria G, Iliev IP et al.; DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with Type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 58(5), 776–783 (2011).
  • GLANT Study Group. A 12-month comparison of ACE inhibitor and CA antagonist therapy in mild-to-moderate essential hypertension – The GLANT Study. Study Group on Long-term Antihypertensive Therapy. Hypertens. Res. 18(3), 235–244 (1995).
  • González-Juanatey JR, Cordero A, Vitale GC, González-Timón B, Mazón P, Bertomeu V. Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study. Rev. Esp. Cardiol. 64(10), 862–868 (2011).
  • Cordero A, Bertomeu-González V, Moreno-Arribas J et al. Burden of systemic hypertension in patients admitted to cardiology hospitalization units. Am. J. Cardiol. 108(11), 1570–1575 (2011).
  • Rosendorff C, Black HR, Cannon CP et al.; American Heart Association Council for High Blood Pressure Research; American Heart Association Council on Clinical Cardiology; American Heart Association Council on Epidemiology and Prevention. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115(21), 2761–2788 (2007).
  • Di Pasquale P, Cannizzaro S, Scalzo S et al. Effects of two different ACE inhibitors, captopril and delapril, in the early phases of acute myocardial infarction. Clin. Drug. Investig. 17(5), 347–355 (1999).
  • Latini R, Staszewsky L, Maggioni AP et al.; Delapril Remodeling after Acute Myocardial Infarction Collaborative Group. Beneficial effects of angiotensin-converting enzyme inhibitor and nitrate association on left ventricular remodeling in patients with large acute myocardial infarction: the Delapril Remodeling after Acute Myocardial Infarction (DRAMI) trial. Am. Heart J. 146(1), 133 (2003).
  • Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 275(20), 1557–1562 (1996).
  • Dalla-Volta S. Delapril versus enalapril in patients with congestive heart failure. Curr. Ther. Res. 60(8), 446–457 (1999).
  • Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371(9623), 1513–1518 (2008).
  • Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 365(9455), 217–223 (2005).
  • Borghi C, Cicero AF. Hypertension: management perspectives. Expert Opin. Pharmacother. 13(14), 1999–2003 (2012).
  • Vijan SG. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J. Indian Med. Assoc. 107(3), 178–182 (2009).
  • Vegter S, Perna A, Hiddema W et al. Cost–effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenet. Genomics 19(9), 695–703 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.